^
    Back
    Association details:
    Biomarker:TMB-H + PD-L1 expression + MSI-L/dMMR
    Cancer:Penile Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Oncol Pharm Pract
    Title:

    Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab

    Published date:
    05/07/2020
    Excerpt:
    We report a case of metastatic penile cancer refractory to TIP chemotherapy, with a dramatic treatment response to ipilimumab and nivolumab. Molecular profiling of this tumor showed a high programmed death ligand-1 expression, high tumor mutational burden, high microsatellite instability, and alterations in DNA mismatch repair genes.
    DOI:
    10.1177/1078155220922602